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Background: Diet-induced obesity leads to metabolic heart disease (MHD) characterized by 
increased oxidative stress that may cause oxidative post-translational modifications (OPTM) of 
cardiac mitochondrial proteins. The functional consequences of OPTM of cardiac mitochondrial 
proteins in MHD are unknown. Our objective was to determine whether cardiac mitochondrial 
dysfunction in MHD due to diet-induced obesity is associated with cysteine OPTM.    
Methods and results: Male C57Bl/6J mice were fed either a high-fat, high-sucrose (HFHS) or 
control diet for 8 months. Cardiac mitochondria from HFHS-fed mice (vs. control diet) had an 
increased rate of H2O2 production, a decreased GSH/GSSG ratio, a decreased rate of complex II 
substrate-driven ATP synthesis and decreased complex II activity. Complex II substrate-driven 
ATP synthesis and complex II activity were partially restored ex-vivo by reducing conditions. A 
biotin switch assay showed that HFHS feeding increased cysteine OPTM in complex II subunits 
A (SDHA) and B (SDHB). Using iodo-TMT multiplex tags we found that HFHS feeding is 
associated with reversible oxidation of cysteines 89 and 231 in SDHA, and 100, 103 and 115 in 
SDHB. 
Conclusions: MHD due to consumption of a HFHS “Western” diet causes increased H2O2 
production and oxidative stress in cardiac mitochondria associated with decreased ATP synthesis 
and decreased complex II activity. Impaired complex II activity and ATP production are 
associated with reversible cysteine OPTM of complex II. Possible sites of reversible cysteine 
OPTM in SDHA and SDHB were identified by iodo-TMT tag labeling. Mitochondrial ROS may 
contribute to the pathophysiology of MHD by impairing the function of complex II. 
 





BIAM - biotin-iodoacetamide 
DTT – dithiothreitol 
GSH/GSSG – ratio of reduced to oxidized glutathione 
HFHS - high fat / high sucrose  
MHD – metabolic heart disease 
OPTM - oxidative post-translational modifications 
ROS – reactive oxygen species 
SDH – succinate dehydrogenase 
SDHA - succinate dehydrogenase subunit A 
SDHB - succinate dehydrogenase subunit B 
SDHC - succinate dehydrogenase subunit C 
SDHD - succinate dehydrogenase subunit D  
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1. Introduction  
 Obesity-related metabolic syndrome increases the risk for metabolic heart disease 
(MHD), a common cardiomyopathy characterized by impaired energetics [1, 2] and myocardial 
dysfunction [3]. The mechanism responsible for impaired energetics in MHD is not understood. 
Another potentially important feature of MHD is increased ROS production within the 
mitochondria [1, 4]. While the role of mitochondrial ROS in the pathophysiology of MHD is not 
known [5], it is increasingly evident that elevated levels of ROS can adversely affect cell 
function by causing oxidative post-translational modifications (OPTM) that regulate protein 
activity [6].  Relatively little is known about OPTM of mitochondrial proteins [7], and no prior 
study has assessed the functional consequences of cardiac mitochondrial protein OPTM in MHD.  
 We recently described the cardiac phenotype in a mouse model of metabolic syndrome 
induced by a “Western-style”, high fat / high sucrose (HFHS) diet [3]. In these mice HFHS 
feeding causes MHD with diastolic dysfunction and elevated oxidative stress in the myocardium 
- both of which are ameliorated by antioxidant therapy [3]. In a preliminary assessment of 
cysteine OPTM using iodo-TMT multiplex tags we found that HFHS feeding is associated with 
reversible OPTM of cysteines in several cardiac mitochondrial proteins [8]. Together these 
observations raised the possibility that impaired energetic function in MHD is due to OPTM of 
mitochondrial proteins. Accordingly, the goal of this study was to test the hypothesis that 
impaired ATP synthesis in HFHS-fed mice is due to reversible cysteine OPTM of one or more 
mitochondrial proteins. As a first approach we evaluated the effect of HFHS feeding on 
mitochondrial function by measuring mitochondrial ATP production, ROS generation, electron 
transport chain complex function, and the ability of a reducing environment to restore function. 
We then used the results of the functional analysis to direct the assessment of reversible OPTM 
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using a biotin switch assay and targeted analysis of a dataset in which reversible cysteine OPTM 
were labeled with iodo-TMT multiplex tags [8].  
 
2. Methods 
 2.1. Experimental animals. Male C57BL/6J mice 9 weeks of age were fed ad libitum 
either a control chow diet (Research Diets, product No. D09071703, 10% kcal lard, 0% sucrose) 
or a HFHS diet (Research Diets, product No. D09071702; 58% kcal lard, 13% kcal sucrose) for 
8 months. Diets were matched for caloric value and full composition is provided in Table S1. By 
two months on diet, HFHS-fed mice weighted more than CD-fed mice and the degree of obesity 
increased progressively over time through 8 months (Figure 1S). The protocol was approved by 
the Institutional Animal Care and Use Committee at Boston University School of Medicine. 
 2.2. Mitochondrial isolation. Heart mitochondria were essentially isolated as previously 
described by us with minor modifications [9]. All steps were performed at 4ºC. Briefly, tissues 
were rinsed in a buffer containing 100 mM KCl, 5 mM EGTA and 5 mM HEPES at pH 7.0, and 
thereafter homogenized in 2 ml of HES buffer (HEPES 5 mM, EDTA 1 mM, Sucrose 0.25M, pH 
7.4 adjusted with KOH 1M) using a Teflon-on-glass electric homogenizer. The homogenate was 
centrifuged at 500 × g for 10 minutes at 4 °C. The supernatant was then centrifuged at 9000 × g 
for 15 minutes at 4ºC and the mitochondrial pellet was resuspended in 100-200 μl of HES buffer 
with 0.2% of BSA fatty acid-free. Protein was quantified using BCA (Pierce) and the value of 
HES-BSA buffer alone was subtracted. 
 2.3. Mitochondrial H2O2 production. Mitochondrial H2O2 production was measured 
using the Amplex Ultra Red-Horseradish peroxidase method (Invitrogen) as described previously 
with minor modifications [10]. This assay is based on the Horseradish peroxidase (2 units/ml) 
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H2O2-dependent oxidation of nonfluorescent Amplex Ultra Red (50 μM) to fluorescent resorufin 
red. In short, 10 μg mitochondria were diluted in 50 μl reaction buffer (125 mM KCl, 10 mM 
HEPES, 5 mM MgCl2, 2 mM K2HPO4, pH 7.44) to determine complex I (pyruvate /malate, 5 
mM) or complex II (succinate, 5 mM) driven H2O2 production with and without inhibitors 
(rotenone 2μM, antimycin A, 0.5μM). Mitochondrial H2O2 production was measured after the 
addition of 50 μl of reaction buffer containing horseradish peroxidase and Amplex Ultra Red. 
Fluorescence was followed at an excitation wavelength of 545 nm and an emission wavelength 
of 590 nm for 20 minutes. The assay is performed in a 96-well plate using a Tecan M1000 plate 
reader. The plate is set up so that all experimental conditions for each animal, as well as a 
standard curve for each run, are acquired and monitored over time simultaneously in duplicate. 
The slope of the increase in fluorescence is converted to the rate of H2O2 production with a 
standard curve. All of the assays were performed at 25 °C. The results are reported as 
pmoles/min/mg protein.  
2.4. Mitochondrial reduced (GSH) and oxidized (GSSG) glutathione measurements. 
Reduced and oxidized glutathione were simultaneously measured as previously described with 
minor modifications [11, 12]. Briefly, mitochondria were lysed in the presence of iodoacetic acid 
(10mM) and derivatized with fluorescent dansyl chloride. Derivatized samples were separated 
and analyzed with hydrophilic interaction liquid chromatography on a Restek Ultra Amino 3um 
100x3.2mm HPLC column at a flow rate of 0.6 ml/min. Buffer A (80% methanol, 20% water) 
was changed in a linear gradient to 30% of buffer B (acetate-buffered (pH 4.6) methanol 
solution) to elute reduced and oxidized glutathione with a Varian ProStar 230 HPLC system. 
Fluorescent products were detected with a Shimadzu RF-10AXL set to 335nm for excitation and 
541nm for emission. 
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2.5. ATP production in isolated mitochondria. ATP synthesis rates in isolated heart 
mitochondria were determined using the luciferin/luciferase based ATP Bioluminescence Assay 
Kit CLS II (Roche) with minor modifications [13]. In short, 10 μg of heart mitochondria were 
suspended in 75 μl buffer A (125 KCl, 10mM Hepes, 5 mM MgCl2 and 2 mM K2HPO4, pH7.44) 
to determine complex I (pyruvate/ malate, 5mM final) or complex II (succinate, 5 mM final) 
driven ATP synthesis. Following standard practice, succinate driven ATP generation was 
measured in the presence of complex I inhibitor rotenone (0.5μM) to avoid the reverse electron 
transfer effect [14]. The assays were performed in the presence and absence of Dithiothreitol 
(DTT, 5mM). Measurements with substrates were repeated in the presence of inhibitors of 
respiratory complex (rotenone (CI) and oligomycin (C IV) to determine the rates of non-
mitochondrial ATP production. The background of the assay was determined with mitochondria 
alone. The measurements for all samples were started simultaneously by adding 75 μl of 
luciferin/luciferase buffer containing 1mM ADP (0.5mM final). The initial slope of the increase 
in ATP-supported luciferase chemiluminescence was used to determine the rate of ATP 
production after subtraction of the background and non-mitochondrial values. Using an ATP 
standard provided in the kit, the slopes were converted in nmoles/min/mg protein. 
 2.6. Mitochondrial ETC complex II activity. Complex II enzyme activity of isolated 
mitochondria was measured using microplate assay kit (Abcam/Mitosciences ab109908/MS241), 
as previously described [15]. In this assay kit, complex II is immunocaptured within the wells of 
the microplate. The production of ubiquinol by complex II is coupled to the reduction of the dye 
DCPIP (2,6-diclorophenolindophenol) and a decreases in its absorbance at 600 nm is measured 
spectrophotometrically. The assay is performed in the presence of succinate as a substrate. The 
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assay was performed in the presence and absence of 5mM DTT. Enzymatic activity was 
normalized to mitochondrial protein concentration. 
 2.7. Immunoblotting for mitochondrial proteins. Immunoblots were performed on 
frozen LV that was homogenized in tissue lysis buffer (HEPES, pH 7.4, 20 mmol/L, B-glycerol 
phosphate 50 mmol/L, EGTA 2 mmol/L, dithiothreitol 1 mmol/L, NaF 10 mmol/L, NaVO4 1 
mmol/L, Triton X-100 1%, glycerol 10%, and 1 protease inhibitor complete mini tablet, EDTA 
free, 20 mL [Roche]). Total protein (25 μg) was separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride membranes. Blots 
were incubated with mouse total OXPHOS Rodent WB Antibody cocktail [containing 5 
antibodies, one each against complex I subunit NDUFB8, complex II subunit B (SDHB), 
complex III Core protein 2 (UQCRC2), complex IV subunit I (MTCO1) and CV alpha subunit 
(ATP5A)]  (Abcam, MA, USA; ab110413), anti-SDHA, SDHB, SDHC (Abcam, MA, USA; 
ab14715, ab14714 and ab155999 respectively) and SDHD (Thermo Fisher; PA5-34387) 
antibodies, anti-VDAC1 (Abcam, MA, USA; ab15895) and anti-GAPDH (Abcam, MA, USA; 
ab8245) and detected with the use of the Licor Odyssey two-color infrared imaging system. 
 2.8. Biotin switch assay. Labeling with biotin iodoacetamide (BIAM; Life Technologies; 
B-1591) was used in a biotin switch assay to detect reversibly oxidized cysteines, as previously 
described by us [16] with minor modifications. Freshly isolated LV sections were immediately 
snap-frozen and stored in liquid nitrogen. Tissue was thawed and lysed in RIPA buffer 
containing 100 mM maleimide (NEM) to block all free thiols and prevent further oxidation. 
Excess NEM was removed by passing the lysates over Zeba™ spin columns. NEM-labeled 
proteins are treated with 5 mM DTT at room temperature for 15 minutes to reduce reversible 
oxidations to free thiols, and again column cleaned to eliminate DTT. Samples are incubated 
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with 4 mM BIAM for 2 hours at room temperature in the dark, labeling any reactive free thiols 
that were previously oxidized. BIAM-labeled proteins are gathered from total protein with 
streptavidin magnetic beads (50 µL) for 1 hour at room temperature in the dark, washed, and 
cleaved from beads by boiling in 30 ml of 2× non-reducing Laemmli buffer for 10min. BIAM-
labeled and unlabelled complex II proteins are detected by western blotting with anti-SDHA, 
SDHB, SDHC (Abcam) and SDHD (Thermo Fisher) antibodies, and bands detected by near-
infrared dye-conjugated secondary antibodies and quantified with the Licor Odyssey two-color 
infrared imaging system. Ratio of labeled to unlabeled proteins represents percentage reversibly 
oxidized cysteines in each specific subunit. 
 2.9. Iodo-TMT multiplex tag labeling of cysteines. We analyzed a dataset previously 
acquired in this model [8] to quantify relative changes in reversible OPTM of complex II 
cysteines. Briefly, proteomic and Thermo iodo-TMT technology was used to differentially-label 
reversibly oxidized and total available cysteines in the left ventricle of HFHS-fed mice. The data 
analysis using Proteome Discoverer (PD) was performed as described [8], with the following 
modification: Direct measurement of the expression of complex II subunits by immunoblotting 
allowed the use of the raw ion intensity sums for reporter ions m/z 129 and 127, which indicate 
HFHS OPTM and CD OPTM respectively, to generate the relative fold-change in reversible 
oxidation.  
 2.10. Statistical analysis. Results are presented as mean±SEM. Comparisons between 
groups were performed using unpaired t-tests, Mann-Whitney non-parametric tests or 2-way 
ANOVA as appropriate. All statistical analyses were performed using GraphPad Prism version 6 





3.1. HFHS diet increases mitochondrial ROS production. In cardiac mitochondria from 
HFHS-fed mice H2O2 production was increased with complex I or II substrates (Figure 1A and 
1B). The cardiac mitochondrial GSH/GSSG ratio was decreased in HFHS-fed mice confirming 
an increase in mitochondrial oxidative stress (Figure 1C). The total myocardial GSH/GSSG 
ratio was likewise decreased in HFHS-fed animals (Figure 1D). 
 3.2. HFHS diet impairs mitochondrial ATP synthesis. In mitochondria from HFHS-fed 
mice ATP synthesis rate was decreased for complex I or II substrates (Figure 2A and 2B). In 
mitochondria from HFHS-fed mice pre-incubation with DTT (5mM) had a minimal effect on 
complex I substrate-driven ATP synthesis (~ 11% increase; p=0.13), but caused a ~33% increase 
with complex II substrate (p=0.01 vs. control diet; p = 0.02 vs. complex I substrate) (Figure 2A 
and 2B). HFHS feeding had no effect on the expression of electron transport complex (ETC) 
subunits or VDAC-1 (Figure 4).  
 3.3. HFHS diet decreases complex II activity. Complex II (succinate dehydrogenase, 
SDH) activity was decreased by ~70% in mitochondria from HFHS-fed mice (Figure 2C). As 
with ATP production rate, DTT (5mM) caused a partial recovery of complex II activity in 
HFHS-fed mice, though not to the levels observed in control diet-fed mice.  
 3.4. HFHS diet causes reversible cysteine OPTM in complex II proteins. To determine 
whether there is reversible cysteine oxidation in complex II proteins, we performed a biotin-
switch assay in which free thiols are blocked with N-Ethylmaleimide - reversibly oxidized thiols 
are then reduced with DTT (as per the ATP and complex II activity assays), labeled with biotin-
iodoacetamide (BIAM) and immunoblotted for complex II subunit proteins. HFHS feeding 
increased the quantity of reversibly-oxidized thiols in SDH subunits A and B (Figure 3). 
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Subunits C and D could not be resolved sufficiently to allow quantitation. However, neither was 
identified as differentially-modified by iodo-TMT/MS.  
 Based on the identification of SDHA and SDHB as sites of reversible cysteine OPTM we 
re-interrogated a proteomics dataset of reversible cysteine OPTM in this model [8] specifically 
focusing on complex II subunits. We found that protein expression of SDHA and SDHB 
assessed by immunoblotting was unchanged (Figure 4), which allowed us to utilize the ratio of 
reversibly-oxidized cysteines between CD and HFHS-fed mice to identify those that are 
differentially oxidized in complex II (Figure 5). This approach is modified from that published 
by our group [8] where relative protein expression was based on the total available cysteines 
tagged by iodo-TMT, rather than actual protein expression. By measuring total protein 
expression, rather than total available cysteines, we increased the accuracy of protein 
determination by discounting the potentially confounding effect of conformational changes and 
irreversible cysteine modifications in these proteins (Table 1). Consistent with the biotin switch 
data, SDHA and SDHB were subject to differential oxidative modifications. In SDHA, Cys89 
and Cys231 OPTM were increased 1.94- and 2.14-fold, respectively in HFHS-fed mice. In 
SDHB, Cys100, Cys103 and Cys115 OPTM were increased 1.43-fold in HFHS-fed mice. 
 
4. Discussion 
 The major new findings of this study are that diet-induced MHD is associated with a) 
increased mitochondrial production of H2O2 and oxidative stress, b) decreased complex I and II-
driven ATP synthesis, c) markedly decreased complex II activity, d) partial rescue of both 
complex II substrate-driven ATP synthesis and complex II activity by a reducing environment, 
and e) reversible cysteine OPTM of complex II subunits SDHA and SDHB. Together these 
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observations provide the first demonstration of reversible cysteine OPTM that are associated 
with mitochondrial dysfunction in MHD.  
 4.1. Impaired mitochondrial ATP synthesis and complex II activity. HFHS feeding was 
associated with decreased ATP synthesis driven by complex I or II substrates. This finding is 
consistent with observations in both humans and animals with obesity. In obese humans 
myocardial energetics assessed by measurement of high energy phosphates using 
31
P NMR are 
impaired [17] and improve with weight loss [18]. Likewise, studies in ob/ob and db/db mice 
show decreased cardiac mitochondrial ATP synthesis [1, 4]. 
 Complex II substrate-driven ATP synthesis was decreased in HFHS-fed mice. Complex 
II couples the oxidation of succinate to fumarate in the matrix with the reduction of ubiquinone 
in the membrane [19]. To assess complex II activity directly we measured the production of 
ubiquinol [15], which demonstrated that HFHS feeding caused a marked decrease in complex II 
activity. Complex II consists of four nuclear-encoded proteins - SDH subunits A, B, C and D. 
SDHA and SDHB are exposed to the matrix, while SDHC and SDHD are in the inner membrane 
[20].  There was no decrease in the expression of SDHA, SDHB or SDHC with HFHS feeding, 
indicating that the observed decrease in function is not due to decreased protein expression. 
Likewise, HFHS feeding was not associated with decreases in representative proteins from 
complex I, III, IV or V; and was not associated with a decrease in mitochondrial mass as 
reflected by VDAC expression (Figure 4).  
 4.2. HFHS-induced cysteine OPTM of complex II. The ability of DTT to partially 
correct complex II substrate-driven ATP synthesis and complex II activity, in the absence of a 
change in complex II protein expression, suggests that the decrease in activity is mediated, at 
least in part, by reversible cysteine OPTM. A large number of proteins involved in cardiac 
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function are subject to cysteine OPTM with effects on function ranging from stimulation to 
inhibition [6, 21, 22], and there are several reactive cysteines in complex II that can be oxidized 
[23, 24]. 
Using the biotin switch assay, we found that HFHS feeding causes reversible cysteine 
OPTM of both SDHA and SDHB. Based on the finding that the expression of SDHA and SDHB 
is unchanged by HFHS feeding, it was possible to further analyze complex II OPTM in a 
database derived using iodo-TMT multiplex tags in HFHS-fed mice [8]. The previous global 
analysis of this dataset determined relative protein expression based on the total available 
cysteines tagged by iodo-TMT [8], which may be confounded by irreversible cysteine 
modifications or conformational changes that limit access to certain cysteines. Because the 
expression of these proteins was determined directly, rather than indirectly based on the total 
number of cysteine, the accuracy of iodo-TMT tag labeling for determination of complex II 
OPTM was increased. This analysis identified OPTM of Cys89 and Cys231 in SDHA, and 
Cys100, Cys103 and Cys115 in SDHB in HFHS-fed mice.  
While we cannot determine which of the identified OPTM are responsible for decreased 
complex II activity, it is noteworthy that Cys100, 103 and 115 are components of the 2Fe-2S 
iron-sulfur cluster which is critical for enzyme activity. Mutations of these sites have been noted 
to lead to decreased enzyme activity in bacteria [25]. Chen et al. [24] showed that S-
glutathiolation of rat SDHA at Cys90 (Cys89 in mouse proteome) increases activity whereas 
ischemia/reperfusion causes de-glutathiolation leading to decreased complex II activity. Since 
the HFHS feeding-associated cysteine OPTM that we observed is associated with decreased 
complex II activity, S-glutathiolation at Cys89 is not likely to be the cause of decreased complex 
II activity with HFHS feeding. Other cysteines of complex II are known to undergo OPTM with 
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unknown functional significance. For example, S-nitrosylation of SDHA Cys536 was observed 
under resting conditions, but not with severe oxidative stress due to ischemia/reperfusion [26], 
while  SDHA Cys430 and SDHC Cys107 were S-nitrosylated in rat myocardium under basal 
conditions [27]. Since the HFHS-induced decrease in complex II activity was only partially 
reversible under reducing conditions,  additional irreversible OPTM of cysteine may be present  
(e.g., sulfonylation) or  OPTM of other amino acids not reducible by DTT occur in this model  
(e.g., lysine) [6].   
 We cannot determine the contribution of complex II OPTM to overall mitochondrial 
dysfunction, or the relative contribution of complex II to overall mitochondrial ATP synthesis. 
However, it appears that the effect of DTT to increase ATP production is relatively specific for 
complex II since it had little or no effect on complex I substrate-driven ATP production. 
Complex II substrate-driven ATP production requires complex V (ATP synthase) function, 
which can be inhibited by glutathiolation in the setting of chronic heart failure [22]. However, 
since DTT did not increase complex I substrate-mediated ATP production, which also requires 
complex V, it is unlikely that the effect of DTT is due to increased complex V activity.  
 Mitochondrial uncoupling was identified in ob/ob and db/db mice [1, 4], and uncoupling 
protein 3 appears to play a role in mitochondrial uncoupling in mice on high fat diet, though not 
in ob/ob mice [28]. While we cannot exclude a role for uncoupling in HFHS-fed mice, the 
decrease in ATP production we observed was reversible for complex II but not complex I 
substrate-driven synthesis, suggesting that uncoupling is unlikely to be the main mechanism 
responsible for impaired ATP synthesis in this setting. 
 4.3. Mitochondrial ROS production in HFHS-fed mice. HFHS diet was associated with 
increased H2O2 production with both complex I and II substrates. The precise mechanism 
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responsible for electron leakage is not clear, but has been ascribed to substrate excess and/or 
reduced activity of ETC [29], the latter potentially related to OPTM-mediated dysfunction of 
ETC proteins. The observed increase in mitochondrial H2O2 production is consistent with prior 
observations in diabetic db/db mice [1]. Since the assay was performed without the addition of 
exogenous SOD, it is possible that the observed rates under- or over-estimate the actual H2O2 
production rate if there are group-specific changes in SOD activity. While the major sources of 
mitochondrial ROS are thought to be complexes I and III, recent evidence suggests that complex 
II may produce ROS in disease states [19, 29]. The potential importance of mitochondrial ROS 
in MHD is supported by the demonstration that transgenic expression of MnSOD was protective 
of myocyte function in diabetic mice [30].  
 4.4. Conclusions. The demonstration that complex II dysfunction in HFHS-fed mice is 
associated with reversible OPTM provides a potential specific mechanism by which 
mitochondrial ROS could contribute to myocardial dysfunction in MHD. We further identified 5 
cysteines which are reversibly-modified by HFHS feeding, and which alone or in combination 
may be responsible for impaired ATP synthesis. These findings suggest that the 
pathophysiologic role of complex II inhibition [19] may extend to MHD. An implication of these 
findings is that cardiac dysfunction in MHD may be a consequence of an ROS-mediated 
impairment in energetics. For example, reduced function of sarcoplasmic reticulum Ca
++
 
ATPase, an enzyme which is highly sensitive to a decrease in ATP, may contribute to diastolic 
dysfunction, a hallmark of MHD [31]. Together these observations suggest that efforts to 
decrease mitochondrial ROS and / or protect target cysteines from oxidation may be of value in 
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Figure 1. Increased H2O2 production rate and decreased GSH/GSSG ratio in cardiac 
mitochondria from mice fed a HFHS vs. control diet. A) H2O2 production rate with a 
complex I substrate (5 mM pyruvate + 5mM malate); B) H2O2 production rate with a 
complex II substrate (5 mM succinate) and inhibition of reverse electron transport (2µM 
rotenone); C) Mitochondrial GSH/GSSG ratio; D) Whole tissue (LV) GSH/GSSG ratio. 
(n=4-5 per group) 
A) H2O2 production – complex I B) H2O2 production – complex II 
C) Mitochondrial GSH/GSSG ratio D) Whole tissue (LV) GSH/GSSG ratio 
Figure 2. Decreased ATP synthesis rate and complex II activity in cardiac mitochondria 
from mice fed a HFHS vs. control diet, and effect of DTT (5 mM). A) Complex I 
substrate-driven ATP synthesis rate (5 mM pyruvate + 5mM malate); B) Complex II 
substrate-driven ATP synthesis rate (5 mM succinate + 2µM rotenone); C) Complex II 
activity assessed by the reduction of ubiquinone. (n=4-5 per group) 
A) ATP synthesis rates – complex I 
B) ATP synthesis rates – complex II 
C) Complex II activity 
HFHS       –      –           +      + 
DTT           –      +           –      + 
HFHS       –       – +      + 
DTT           –       +           –      + 
HFHS       –       – +      + 
DTT           –       +           –      + 
Figure 3. Biotin switch assay to detect reversibly-oxidized cysteines on SDHA and 
SDHB. A) Representative blots from biotin switch assay in which total represents protein 
labeled by the antibody for SDHA or SDHB, and BIAM represents the portion of total 
protein containing a reversible cysteine OPTM. B and C) Bar graphs showing the mean 
values for the ratio of BIAM-labeled to total protein, reflecting the proportion of reversibly-
oxidized cysteines in SDHA (Panel B) or SDHB (Panel C). (n=3-4 per group) MW – 
molecular weight markers 
A) Biotin switch representative blots 
B) SDHA : Reversibly-oxidized 
cysteines (% total) 
C) SDHB : Reversibly-oxidized 
cysteines (% total) 
CD HFHS 








SDHA – 75kD 
SDHB – 30kD 
MW 
Figure 4. ETC protein and VDAC-1 expression. Expression of representative proteins the 
complexes of ETC (1 each from complex I, III, IV and V, and 2 from complex II). A) 
Representative Western blots. B) Mean values. VDAC-1 is indexed to GAPDH, and ETC 
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Figure 5. Data analysis of reversible cysteine oxidation (representative example). A precursor ion 
from SDHA with mass-to-charge ratio (m/z) 677.35 was subjected to MS/MS in the Thermo Q Exactive 
Mass Spectrometer. Brackets within the peptide sequence indicate b (N-terminal) and y (C-terminal) 
fragment ions; their respective peaks are labeled in the MS/MS spectrum. Mascot software works 
backward from the fragment masses to identify the most likely sequence match, which in this case was 
AAFGLSEAGFNTAcLTK, or cys-89. For each identified cysteine, reporter ion masses were detected in 
the low mass region (m/z 126-129) of the tandem mass spectrum. The intensities of m/z 127 and 129 
represent the magnitude of reversible cysteine OPTM (m/z) for Control and HFHS, respectively. Given 
unchanged protein expression (see Figure 4), we compared these ions directly. This particular cysteine 
was oxidized 1.94 in the HFHS-fed mice compared to control diet fed. 
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Table 1S. Composition of HFHS and control diets. D09071702 is HFHS diet and D09071703 




Figure 1S. HFHS-fed mice develop progressive obesity starting at 2 months on diet. 
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